ABSTRACT
Background Evidence regarding sex-related differences in response to transcatheter aortic valve implantation according to the valve type is lacking. This study sought to evaluate the impact of sex on the treatment effect of Evolut-PRO/PRO+ (PRO) or Sapien 3 Ultra (ULTRA) devices on clinical outcomes.
Methods Comparative Analysis of Evolut PRO vs Sapien 3 Ultra Valves for Transfemoral Transcatheter Aortic Valve Implantation (OPERA-TAVI) is a multicenter multinational registry including patients undergoing latest-iteration PRO or ULTRA implantation. Overall, 1174 out of 1897 patients were matched based on valve type and compared according to sex, while 470 males and 630 females were matched and compared according to valve type. Thirty-day and 1-year outcomes were evaluated.
Results In both PRO and ULTRA group, males had a higher comorbidity burden, while females had smaller aortic root. Both 30-day (device success [DS], early safety outcome, permanent pacemaker implantation [PPI], patient-prosthesis mismatch [PPM], paravalvular regurgitation [PVR], bleedings, vascular complications, and all-cause death) and 1-year outcomes (all-cause death, stroke and heart failure hospitalization) did not differ according to sex in both valve groups. However, male sex decreased the likelihood of 30-day DS with ULTRA versus PRO (p for interaction 0.047). A higher risk of 30-day PPI and 1-year stroke, and a lower risk of PPM was observed in PRO versus ULTRA, regardless of sex. No other differences were noted.
Conclusions Sex did not modify the treatment effect of PRO versus ULTRA on clinical outcomes, with the exception of 30-day DS that was decreased in males (versus females) receiving ULTRA (versus PRO).
Competing Interest Statement
Dr Adamo has received speaker fees form Abbott. Dr Pilgrim Thomas Pilgrim reports research, travel or educational grants to the institution without personal remuneration from Biotronik, Boston Scientific, Edwards Lifesciences, and ATSens; speaker fees and consultancy fees to the institution from Biotronik, Boston Scientific, Edwards Lifesciences, Abbott, Medtronic, Biosensors, and Highlife. Dr Abdel-Wahab's institution hasreceived speaker honoraria and/or consultancy fees on his behalf from Boston Scientific and Medtronic. Dr Garot has served as medical director and being a shareholder of CERC, a CRO dedicated to cardiovascular diseases; and has received speaker/consultancy fees from Abbott, Biosensors, Boston Scientific, Edwards Lifesciences, and General Electric HealthCare. Dr Latib has served on advisory boards or as a consultant for Medtronic, Boston Scientific, Philips, Edwards Lifesciences, and Abbott. Dr Mylotte is a consultant for Medtronic, Boston Scientific, and Microport. Dr De Backer has received institutional research grants and/or consulting fees from Abbott and Boston Scientific. Dr Akodad has received research funding from Medtronic, Biotronik, MUSE-Explore, Villa M, and Federation Française de Cardiologie. Dr Meier is supported by the Swiss National Science Foundation (grant P2LAP3_199561). Dr Søndergaard has received consultant fees and/or institutional research grants from Abbott, Boston Scientific, Medtronic, and SMT. Dr Tamburino is consultant for Medtronic. Dr. Metra has received consulting fees from Abbott Vascular, Actelion, Amgen, AstraZeneca, Bayer, Edwards Therapeutics, Livanova, Servier, Vifor Pharma, and WindTree Therapeutics. Dr Barbanti is a consultant for Boston Scientific, Edwards Lifesciences, and Medtronic.All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Clinical Trial
NA
Funding Statement
No funding were obtained for this study
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
NA
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* Dr Adamo and Dr Branca are joint first authors
↵# Dr Costa and Dr Barbanti are joint senior authors
Potential conflicts of interest: Dr Adamo has received speaker fees form Abbott. Dr Pilgrim Thomas Pilgrim reports research, travel or educational grants to the institution without personal remuneration from Biotronik, Boston Scientific, Edwards Lifesciences, and ATSens; speaker fees and consultancy fees to the institution from Biotronik, Boston Scientific, Edwards Lifesciences, Abbott, Medtronic, Biosensors, and Highlife. Dr Abdel-Wahab’s institution hasreceived speaker honoraria and/or consultancy fees on his behalf from Boston Scientific and Medtronic. Dr Garot has served as medical director and being a shareholder of CERC, a CRO dedicated to cardiovascular diseases; and has received speaker/consultancy fees from Abbott, Biosensors, Boston Scientific, Edwards Lifesciences, and General Electric HealthCare. Dr Latib has served on advisory boards or as a consultant for Medtronic, Boston Scientific, Philips, Edwards Lifesciences, and Abbott. Dr Mylotte is a consultant for Medtronic, Boston Scientific, and Microport. Dr De Backer has received institutional research grants and/or consulting fees from Abbott and Boston Scientific. Dr Akodad has received research funding from Medtronic, Biotronik, MUSE-Explore, Villa M, and Federation Française de Cardiologie. Dr Meier is supported by the Swiss National Science Foundation (grant P2LAP3_199561). Dr Søndergaard has received consultant fees and/or institutional research grants from Abbott, Boston Scientific, Medtronic, and SMT. Dr Tamburino is consultant for Medtronic. Dr. Metra has received consulting fees from Abbott Vascular, Actelion, Amgen, AstraZeneca, Bayer, Edwards Therapeutics, Livanova, Servier, Vifor Pharma, and WindTree Therapeutics. Dr Barbanti is a consultant for Boston Scientific, Edwards Lifesciences, and Medtronic.All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Data Availability
Data analyzed in this study will be available if needed subject to Dr Barbanti's authorization
